Zenas BioPharma Files 10-Q, Details Xencor & Viridian Ties

Ticker: ZBIO · Form: 10-Q · Filed: May 15, 2025 · CIK: 1953926

Sentiment: neutral

Topics: 10-Q, biotech, agreements, pharmaceuticals

TL;DR

Zenas BioPharma 10-Q filed. Details on Xencor & Viridian agreements. Check financials.

AI Summary

Zenas BioPharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary business is in pharmaceutical preparations. Key relationships and agreements mentioned include those with Xencor, Inc. and Viridian Therapeutics, Inc., with specific dates and terms noted in the filing.

Why It Matters

This filing provides insight into Zenas BioPharma's ongoing operational and financial status, including its material relationships with other biotech companies.

Risk Assessment

Risk Level: medium — Biotech companies often face inherent risks related to drug development, regulatory approvals, and market competition, which are not fully detailed in this summary.

Key Players & Entities

FAQ

What is the primary business of Zenas BioPharma, Inc.?

Zenas BioPharma, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].

When is the period covered by this 10-Q filing?

This 10-Q filing covers the period ending on March 31, 2025.

What are some key related parties or agreements mentioned in the filing?

The filing mentions relationships and agreements with Xencor, Inc. and Viridian Therapeutics, Inc., with specific agreement dates like May 31, 2021, and January 31, 2025.

What is the SEC file number for Zenas BioPharma, Inc.?

The SEC file number for Zenas BioPharma, Inc. is 001-42270.

Where is Zenas BioPharma, Inc. located?

Zenas BioPharma, Inc. is located at 852 Winter Street, Suite 250, Waltham, MA 02451.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Zenas BioPharma, Inc. (ZBIO).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing